- CEO
- Hong Wei Yang
- Full Time Employees
- 4,372
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Shanghai China
- IPO Date
- May 17, 2022
- Business
- SMO ClinPlus Co., Ltd. Class A is a China-based site management organization (SMO) specializing in clinical trial execution and management services for the pharmaceutical, biotechnology, and medical device industries. Founded in 2009 and headquartered in Shanghai, China, the company provides comprehensive clinical research support services to global pharmaceutical multinational corporations, domestic innovative biopharmaceutical developers, and contract research organizations (CROs). The company's core offerings encompass clinical trial execution strategy modeling; site selection and study start-up (SSU) services, including protocol feasibility assessments, ethics committee application filings, site contract negotiations, and trial initiation coordination; on-site clinical research coordinator (CRC) dispatch and execution management, comprising subject screening, patient recruitment and retention, clinical visit coordination, electronic case report form (eCRF) data entry, source document verification, investigational product accountability, and biological sample management; functional service provider (FSP) resourcing models; third-party clinical quality assurance, site audit, and Good Clinical Practice (GCP) compliance training; and institutional site support services, including standard operating procedure development and trial management platform deployment. Operating nationwide across more than 200 Chinese cities and maintaining active collaborations with nearly 1,000 clinical trial institutions, the company supports clinical programs across key therapeutic areas such as oncology, hematology, cardiovascular diseases, endocrinology, dermatology, and infectious diseases. In recent operational and strategic developments, ClinPlus has advanced the technological integration of its service delivery through the deployment of its proprietary Ruixing Clinical Trial Intelligent Management Platform and its registered Ruixing Clinical Trial Text Generation Algorithm, introducing artificial intelligence-enabled automated medical documentation, intelligent patient recruitment modeling, and electronic Trial Master File (e-TMF) quality inspection workflows. Additionally, the company has expanded its early-phase (Phase I and Phase II) clinical trial contract pipeline, increased market share among domestic biopharmaceutical developers pursuing cross-border licensing transactions, and broadened its domestic operating infrastructure through subsidiaries including Ruixin (Ganzhou) Medical Technology Development Co., Ltd.